文献速递慢阻肺哮喘间质性肺疾病

表型年龄加速与遗传风险对慢性呼吸系统疾病发病的联合关联:英国生物银行前瞻性队列研究

Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
PubMed 文献 · Eur Respir J · 2024-02-22

基于英国生物银行308 592名基线参与者的前瞻性队列,计算基于9项临床化学标志物的表型年龄加速(PhenoAgeAccel),分析其与特发性肺纤维化(IPF)、慢阻肺(COPD)和哮喘发病及肺功能的关联。结果显示PhenoAgeAccel每增加5年与IPF(HR 1.52)、COPD(HR 1.54)和哮喘(HR 1.18)风险升高及肺功能下降相关,且与遗传风险存在相加交互,高遗传风险且生物学衰老更明显者发病风险最高。

要点

  • PhenoAgeAccel每增加5年与IPF、COPD和哮喘发病风险升高相关。
  • PhenoAgeAccel与IPF和COPD的遗传风险存在相加交互作用。
  • 高遗传风险且生物学衰老更明显者IPF、COPD和哮喘风险最高。

核心结论

  • PhenoAgeAccel与常见慢性呼吸系统疾病发病风险升高及肺功能下降显著相关,可能作为新型临床生物标志物。

研究设计与样本

  • 前瞻性队列研究,纳入英国生物银行308 592名基线参与者。
  • PhenoAgeAccel由表型年龄对实际年龄回归计算,表型年龄基于实际年龄和9项临床化学标志物。
  • 构建多基因风险评分,评估PhenoAgeAccel是否修饰遗传易感性对慢性呼吸系统疾病和肺功能的影响。

主要发现

  • PhenoAgeAccel每增加5年与IPF风险升高相关(HR 1.52,95% CI 1.45-1.59)。
  • PhenoAgeAccel每增加5年与COPD风险升高相关(HR 1.54,95% CI 1.51-1.57)。
  • PhenoAgeAccel每增加5年与哮喘风险升高相关(HR 1.18,95% CI 1.15-1.20)。
  • PhenoAgeAccel与肺功能下降相关。
  • 高遗传风险且生物学衰老更明显者IPF风险最高(HR 5.24,95% CI 3.91-7.02)、COPD风险最高(HR 2.99,95% CI 2.66-3.36)、哮喘风险最高(HR 2.07,95% CI 1.86-2.31)。

关键数值与推荐

  • 表型年龄计算纳入白蛋白、碱性磷酸酶、肌酐、葡萄糖、C反应蛋白、淋巴细胞百分比、平均红细胞体积、红细胞分布宽度和白细胞计数。
  • PhenoAgeAccel与IPF和COPD的遗传风险存在相加交互作用。
  • 中介分析提示PhenoAgeAccel可中介吸烟与慢性呼吸系统疾病关联的10~20%。
  • PhenoAgeAccel可中介空气动力学直径<2.5 µm颗粒物与上述疾病关联的约10%。

临床怎么用

  • PhenoAgeAccel可作为识别慢性呼吸系统疾病高危人群的潜在临床生物标志物。
  • 对高遗传风险且生物学衰老明显者,可加强IPF、COPD和哮喘的风险监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accelerated biological ageing has been associated with an increased risk of several chronic respiratory diseases. However, the associations between phenotypic age, a new biological age indicator based on clinical chemistry biomarkers, and common chronic respiratory diseases have not been evaluated. METHODS: We analysed data from 308 592 participants at baseline in the UK Biobank. The phenotypic age was calculated from chronological age and nine clinical chemistry biomarkers, including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percent, mean cell volume, red cell distribution width and white blood cell count. Furthermore, phenotypic age acceleration (PhenoAgeAccel) was calculated by regressing phenotypic age on chronological age. The associations of PhenoAgeAccel with incident common chronic respiratory diseases and cross-sectional lung function were investigated. Moreover, we constructed polygenic risk scores and evaluated whether PhenoAgeAccel modified the effect of genetic susceptibility on chronic respiratory diseases and lung function. RESULTS: The results showed significant associations of PhenoAgeAccel with increased risk of idiopathic pulmonary fibrosis (IPF) (hazard ratio (HR) 1.52, 95% CI 1.45-1.59), COPD (HR 1.54, 95% CI 1.51-1.57) and asthma (HR 1.18, 95% CI 1.15-1.20) per 5-year increase and decreased lung function. There was an additive interaction between PhenoAgeAccel and the genetic risk for IPF and COPD. Participants with high genetic risk and who were biologically older had the highest risk of incident IPF (HR 5.24, 95% CI 3.91-7.02), COPD (HR 2.99, 95% CI 2.66-3.36) and asthma (HR 2.07, 95% CI 1.86-2.31). Mediation analysis indicated that PhenoAgeAccel could mediate 10∼20% of the associations between smoking and chronic respiratory diseases, while ∼10% of the associations between particulate matter with aerodynamic diameter <2.5 µm and the disorders were mediated by PhenoAgeAccel. CONCLUSION: PhenoAgeAccel was significantly associated with incident risk of common chronic respiratory diseases and decreased lung function and could serve as a novel clinical biomarker.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Wang T, Duan W, Jia X, et al. Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study. Eur Respir J. 2024. PMID: 38061785. doi:10.1183/13993003.01720-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。